Characteristics of Skin Disease related to COVID-19 infection in RSUP Dr. M. Djamil Padang: Retrospective Study
DOI:
https://doi.org/10.66344/jpad.v33i3.2246Keywords:
Skin disease, COVID-19Abstract
Objective To identify the clinical characteristics skin diseases encountered in COVID-19-infected patients receiving therapy at Dr. M. Djamil Hospital Padang.
Methods This research is a retrospective study with a sample of 49 COVID-19 patients with skin disorders treated at Dr. M. Djamil Hospital Padang from March 2020-October 2021.
Results From the medical record data, 49 patients with skin disorders were enrolled with 25 women (51%) and 24 men (49%). With the common age being 45-65 years, as many as 19 people (39%), and the minor age being 0-11 months; one person (2%). The most extended length of stay was 11-15 days for as many as 17 people (35%). Erythema, chilblains, and urticaria are some skin disorders suspected of being a skin manifestation of COVID-19 infection. The most common skin disorders accompanied with COVID-19 infection are SLE, irritant contact dermatitis and ulcers.
Conclusion It can be challenging to distinguish between various skin conditions and COVID-19 skin symptoms. According to this study, the most common symptoms of COVID-19 patients were erythema, chilblains, and urticaria.
References
1. Li. Q. Early Transmission dynamics in Wuhan, China of Novel Coronavirus Infected Pneumonia. NEJM. 2020;1199-07.
2. Rothan H.A. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;1-4.
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.
4. Henry, D. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(6):e244-e245.
5. S. Recalcati, Acral Cutaneous Lesions in the Time of COVID-19. J Eur Acad Dermatol Venereol. 2020;34(8):e346-e347.
6. Gianotti R., Zerbi P., Dodiuk-Gad R. Histopathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy. J Cosmet Dermatol. Sci.2020;98(2):141-3.
7. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7.
8. Rosell-Díaz A., Mateos-Mayo A., Nieto-Benito L., Balaguer-Franch I., De La Torre-Ruiz E.H., Lainez-Nuez A., Suárez-Fernández R., Bergón-Sendín M. Exanthema and eosinophilia in COVID-19 patients: Has viral infection a role in drug-induced exanthemas? J Eur Acad Dermatol Venereol. 2020;34:561.
9. Tamai M., Maekawa A., Goto N., Ge L., Nishida T., Iwahashi H., Yokomi A. Three cases of COVID-19 patients presenting with erythema. J Dermatol. 2020;47:1175-78.
10. Vázquez-Osorio I, Rocamonde L, Treviño-Castellano M, Vázquez-Veiga H, Ginarte M. Pseudo-chilblain lesions and COVID-19: a controversial relationship. Int J Dermatol. 2021;60(6):754-6. doi:10.1111/ijd.15422.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Marina Harahap
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
